Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world drug survival of ixekizumab for psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exploring the hereditary background of renal cancer in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genomisk medicin til præimplantations-, 
præ- og postnatal diagnostik

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Toward mechanistic models for genotype-phenotype correlations in phenylketonuria using protein stability calculations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A new family with a homozygous nonsense variant in NTHL1 further delineated the clinical phenotype of NTHL1-associated polyposis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GenoMEL Study Group
Vis graf over relationer

BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved.

METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics.

RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance.

CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.

OriginalsprogEngelsk
TidsskriftJournal of the American Academy of Dermatology
Vol/bind81
Udgave nummer2
Sider (fra-til)386-394
Antal sider9
ISSN0190-9622
DOI
StatusUdgivet - aug. 2019

Bibliografisk note

Copyright © 2019 American Academy of Dermatology, Inc. All rights reserved.

ID: 58278756